VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q55313466  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241120235937.0
008     241120nneanz||abbn n and d
035 ‎‡a  (WKP)Q55313466‏
024 ‎‡a  0000-0002-9902-6096‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q55313466‏
100 0 ‎‡a  John P. Moore‏ ‎‡9  ast‏ ‎‡9  sq‏ ‎‡9  sl‏ ‎‡9  es‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  জন পি মুর‏ ‎‡9  bn‏
400 0 ‎‡a  John P. Moore‏ ‎‡c  American virologist, researcher, and professor‏ ‎‡9  en‏
400 0 ‎‡a  John P. Moore‏ ‎‡c  viroloog‏ ‎‡9  nl‏
670 ‎‡a  Author's A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses‏
670 ‎‡a  Author's A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.‏
670 ‎‡a  Author's A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells‏
670 ‎‡a  Author's A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene‏
670 ‎‡a  Author's A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo‏
670 ‎‡a  Author's A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies‏
670 ‎‡a  Author's A Plea for Justice for Jailed Medical Workers‏
670 ‎‡a  Author's A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield‏
670 ‎‡a  Author's A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells‏
670 ‎‡a  Author's Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.‏
670 ‎‡a  Author's AIDS/HIV. A STEP into darkness or light?‏
670 ‎‡a  Author's An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability‏
670 ‎‡a  Author's An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells‏
670 ‎‡a  Author's Animal models for microbicide studies‏
670 ‎‡a  Author's Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike‏
670 ‎‡a  Author's Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization‏
670 ‎‡a  Author's Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env‏
670 ‎‡a  Author's Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes‏
670 ‎‡a  Author's Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission‏
670 ‎‡a  Author's Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.‏
670 ‎‡a  Author's Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.‏
670 ‎‡a  Author's Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.‏
670 ‎‡a  Author's Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans‏
670 ‎‡a  Author's Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers‏
670 ‎‡a  Author's Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide‏
670 ‎‡a  Author's CD4-induced activation in a soluble HIV-1 Env trimer‏
670 ‎‡a  Author's Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands‏
670 ‎‡a  Author's cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate‏
670 ‎‡a  Author's Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation‏
670 ‎‡a  Author's Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells‏
670 ‎‡a  Author's Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes‏
670 ‎‡a  Author's Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers‏
670 ‎‡a  Author's Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer‏
670 ‎‡a  Author's Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies‏
670 ‎‡a  Author's Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer‏
670 ‎‡a  Author's Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer‏
670 ‎‡a  Author's Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.‏
670 ‎‡a  Author's Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens‏
670 ‎‡a  Author's Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens‏
670 ‎‡a  Author's Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies‏
670 ‎‡a  Author's Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits‏
670 ‎‡a  Author's Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1‏
670 ‎‡a  Author's Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer‏
670 ‎‡a  Author's Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.‏
670 ‎‡a  Author's Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses‏
670 ‎‡a  Author's Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro.‏
670 ‎‡a  Author's Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance‏
670 ‎‡a  Author's Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle‏
670 ‎‡a  Author's Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins‏
670 ‎‡a  Author's Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes‏
670 ‎‡a  Author's Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types‏
670 ‎‡a  Author's Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?‏
670 ‎‡a  Author's Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors‏
670 ‎‡a  Author's Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo‏
670 ‎‡a  Author's Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.‏
670 ‎‡a  Author's Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1‏
670 ‎‡a  Author's Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41‏
670 ‎‡a  Author's Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure‏
670 ‎‡a  Author's Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin‏
670 ‎‡a  Author's Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines‏
670 ‎‡a  Author's High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers‏
670 ‎‡a  Author's HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors‏
670 ‎‡a  Author's HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies‏
670 ‎‡a  Author's HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells‏
670 ‎‡a  Author's HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells‏
670 ‎‡a  Author's HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers‏
670 ‎‡a  Author's HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1 complex‏
670 ‎‡a  Author's HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers‏
670 ‎‡a  Author's HIV: A stamp on the envelope‏
670 ‎‡a  Author's HIV's Achilles' Heel‏
670 ‎‡a  Author's How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?‏
670 ‎‡a  Author's Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells‏
670 ‎‡a  Author's IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines‏
670 ‎‡a  Author's Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice‏
670 ‎‡a  Author's Immunogenicity in rabbits of SOSIP trimers from clades A, B and C, given individually, sequentially or in combinations‏
670 ‎‡a  Author's Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes‏
670 ‎‡a  Author's Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.‏
670 ‎‡a  Author's Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization‏
670 ‎‡a  Author's Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities‏
670 ‎‡a  Author's Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers‏
670 ‎‡a  Author's Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein‏
670 ‎‡a  Author's Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages‏
670 ‎‡a  Author's Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?‏
670 ‎‡a  Author's Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function‏
670 ‎‡a  Author's Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody‏
670 ‎‡a  Author's Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission‏
670 ‎‡a  Author's Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates‏
670 ‎‡a  Author's Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.‏
670 ‎‡a  Author's Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity‏
670 ‎‡a  Author's N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus‏
670 ‎‡a  Author's Native-like Env trimers as a platform for HIV-1 vaccine design‏
670 ‎‡a  Author's Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin‏
670 ‎‡a  Author's Neutralizing antibody responses induced by HIV-1 envelope glycoprotein SOSIP trimers derived from elite neutralizers‏
670 ‎‡a  Author's Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.‏
670 ‎‡a  Author's Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.‏
670 ‎‡a  Author's Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein‏
670 ‎‡a  Author's Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells‏
670 ‎‡a  Author's P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand.‏
670 ‎‡a  Author's Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers‏
670 ‎‡a  Author's Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.‏
670 ‎‡a  Author's Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques‏
670 ‎‡a  Author's Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application‏
670 ‎‡a  Author's Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation‏
670 ‎‡a  Author's Potent induction of antibody-secreting B-cells by human dermal-derived CD14+ dendritic cells triggered by dual toll-like receptor ligation‏
670 ‎‡a  Author's Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity‏
670 ‎‡a  Author's Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.‏
670 ‎‡a  Author's Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor‏
670 ‎‡a  Author's Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion‏
670 ‎‡a  Author's Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor‏
670 ‎‡a  Author's Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.‏
670 ‎‡a  Author's Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in Vitro‏
670 ‎‡a  Author's Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies‏
670 ‎‡a  Author's Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.‏
670 ‎‡a  Author's Recombinant gp120, antibodies to the V3 region of gp120, and neural progenitor cells‏
670 ‎‡a  Author's Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex‏
670 ‎‡a  Author's Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers‏
670 ‎‡a  Author's Refocussing Antibody Responses by Chemical Modification of Vaccine Antigens‏
670 ‎‡a  Author's Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.‏
670 ‎‡a  Author's Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.‏
670 ‎‡a  Author's SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds‏
670 ‎‡a  Author's Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.‏
670 ‎‡a  Author's SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses‏
670 ‎‡a  Author's Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein‏
670 ‎‡a  Author's Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen‏
670 ‎‡a  Author's SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers‏
670 ‎‡a  Author's Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.‏
670 ‎‡a  Author's Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers‏
670 ‎‡a  Author's Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.‏
670 ‎‡a  Author's Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers‏
670 ‎‡a  Author's Stabilized HIV-1 Envelope Glycoprotein Trimers Lacking the V1V2 Domain, Obtained by Virus Evolution‏
670 ‎‡a  Author's Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies‏
670 ‎‡a  Author's Structural and biological mimicry of protein surface recognition by  / -peptide foldamers‏
670 ‎‡a  Author's Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens‏
670 ‎‡a  Author's Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers‏
670 ‎‡a  Author's Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers‏
670 ‎‡a  Author's Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers‏
670 ‎‡a  Author's Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence‏
670 ‎‡a  Author's Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120‏
670 ‎‡a  Author's Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination‏
670 ‎‡a  Author's Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques‏
670 ‎‡a  Author's T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers‏
670 ‎‡a  Author's Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens‏
670 ‎‡a  Author's Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses‏
670 ‎‡a  Author's Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients‏
670 ‎‡a  Author's The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence‏
670 ‎‡a  Author's The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles‏
670 ‎‡a  Author's The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.‏
670 ‎‡a  Author's Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation‏
670 ‎‡a  Author's Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.‏
670 ‎‡a  Author's Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures‏
670 ‎‡a  Author's Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.‏
670 ‎‡a  Author's Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry‏
670 ‎‡a  Author's Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.‏
670 ‎‡a  Author's Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.‏
670 ‎‡a  Author's V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc‏
670 ‎‡a  Author's V3: HIV's switch-hitter‏
670 ‎‡a  Author's What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?‏
670 ‎‡a  Author's Which topical microbicides for blocking HIV-1 transmission will work in the real world?‏
670 ‎‡a  wikidata site links‏ ‎‡u  https://en.wikipedia.org/wiki/John_P._Moore‏
909 ‎‡a  (orcid) 0000000299026096‏ ‎‡9  1‏
919 ‎‡a  sarscov2vaccineswarpspeedneedsmindmeldsnotwarpedminds‏ ‎‡A  SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds‏ ‎‡9  1‏
919 ‎‡a  resistanceofahumanimmunodeficiencyvirustype1isolatetoasmallmoleculeccr5inhibitorcaninvolvesequencechangesinbothgp120andgp41‏ ‎‡A  Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.‏ ‎‡9  1‏
919 ‎‡a  refocussingantibodyresponsesbychemicalmodificationofvaccineantigens‏ ‎‡A  Refocussing Antibody Responses by Chemical Modification of Vaccine Antigens‏ ‎‡9  1‏
919 ‎‡a  reducingv3antigenicityandimmunogenicityonsolublenativelikehiv1envsosiptrimers‏ ‎‡A  Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers‏ ‎‡9  1‏
919 ‎‡a  recombinanthivenvelopetrimerselectsforquaternarydependentantibodiestargetingthetrimerapex‏ ‎‡A  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex‏ ‎‡9  1‏
919 ‎‡a  recombinantgp120antibodiestothev3regionofgp120andneuralprogenitorcells‏ ‎‡A  Recombinant gp120, antibodies to the V3 region of gp120, and neural progenitor cells‏ ‎‡9  1‏
919 ‎‡a  recognitionofhivinactivatingpeptidetriazolesbytherecombinantsolubleenvtrimerbg505sosip664‏ ‎‡A  Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.‏ ‎‡9  1‏
919 ‎‡a  recognitionandpenetrationofthehiv1envglycanshieldbypotentbroadlyneutralizingantibodies‏ ‎‡A  Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies‏ ‎‡9  1‏
919 ‎‡a  sequentialandsimultaneousimmunizationofrabbitswithhiv1envelopeglycoproteinsosip664trimersfromcladesaband100‏ ‎‡A  Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.‏ ‎‡9  1‏
919 ‎‡a  shiv162p3infectionofrhesusmacaquesgivenmaravirocgelvaginallydoesnotinvolveresistantviruses‏ ‎‡A  SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses‏ ‎‡9  1‏
919 ‎‡a  shortcommunicationvirionaggregationbyneutralizingandnonneutralizingantibodiestothehiv1envelopeglycoprotein‏ ‎‡A  Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein‏ ‎‡9  1‏
919 ‎‡a  ratmonoclonalantibodiestononoverlappingepitopesofhumanimmunodeficiencyvirustype1gp120blockcd4bindinginvitro‏ ‎‡A  Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in Vitro‏ ‎‡9  1‏
919 ‎‡a  sitespecificglycosylationofvirionderivedhiv1envismimickedbyasolubletrimericimmunogen‏ ‎‡A  Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen‏ ‎‡9  1‏
919 ‎‡a  sosandipmodificationspredominantlyaffecttheyieldbutnototherpropertiesofsosip664hiv1envglycoproteintrimers‏ ‎‡A  SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers‏ ‎‡9  1‏
919 ‎‡a  quantitativemodelofantibodyandsolublecd4mediatedneutralizationofprimaryisolatesandtcelllineadaptedstrainsofhumanimmunodeficiencyvirustype1‏ ‎‡A  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.‏ ‎‡9  1‏
919 ‎‡a  specificaminoacidsinthenterminusofthegp41ectodomaincontributetothestabilizationofasolublecleavedgp140envelopeglycoproteinfromhumanimmunodeficiencyvirustype1‏ ‎‡A  Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.‏ ‎‡9  1‏
919 ‎‡a  stabilizationofthegp120v3loopthroughhydrophobicinteractionsreducestheimmunodominantv3directednonneutralizingresponsetohiv1envelopetrimers‏ ‎‡A  Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers‏ ‎‡9  1‏
919 ‎‡a  protectionofrhesusmacaquesfromvaginalinfectionbyvaginallydeliveredmaravirocaninhibitorofhiv1entryviatheccr5coreceptor‏ ‎‡A  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor‏ ‎‡9  1‏
919 ‎‡a  stabilizationofthesolublecleavedtrimericformoftheenvelopeglycoproteincomplexofhumanimmunodeficiencyvirustype1‏ ‎‡A  Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.‏ ‎‡9  1‏
919 ‎‡a  stabilizationofthev2loopimprovesthepresentationofv2loopassociatedbroadlyneutralizingantibodyepitopesonhiv1envelopetrimers‏ ‎‡A  Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers‏ ‎‡9  1‏
919 ‎‡a  protectionofmacaquesfromvaginalshivchallengebyvaginallydeliveredinhibitorsofviruscellfusion‏ ‎‡A  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion‏ ‎‡9  1‏
919 ‎‡a  stabilizedhiv1envelopeglycoproteintrimerslackingthev1v2domainobtainedbyvirusevolution‏ ‎‡A  Stabilized HIV-1 Envelope Glycoprotein Trimers Lacking the V1V2 Domain, Obtained by Virus Evolution‏ ‎‡9  1‏
919 ‎‡a  stable293tandchocelllinesexpressingcleavedstablehiv1envelopeglycoproteintrimersforstructuralandvaccinestudies‏ ‎‡A  Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies‏ ‎‡9  1‏
919 ‎‡a  structuralandbiologicalmimicryofproteinsurfacerecognitionbypeptidefoldamers‏ ‎‡A  Structural and biological mimicry of protein surface recognition by  / -peptide foldamers‏ ‎‡9  1‏
919 ‎‡a  structuralandfunctionalevaluationofdenovodesigned2componentnanoparticlecarriersforhivenvtrimerimmunogens‏ ‎‡A  Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens‏ ‎‡9  1‏
919 ‎‡a  structuralcharacterizationofcleavedsolublehiv1envelopeglycoproteintrimers‏ ‎‡A  Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers‏ ‎‡9  1‏
919 ‎‡a  protectionofmacaquesfromvaginalshivchallengebyanorallydeliveredccr5inhibitor‏ ‎‡A  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor‏ ‎‡9  1‏
919 ‎‡a  structuralconstraintsdeterminetheglycosylationofhiv1envelopetrimers‏ ‎‡A  Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers‏ ‎‡9  1‏
919 ‎‡a  preventionofvirustransmissiontomacaquemonkeysbyavaginallyappliedmonoclonalantibodytohiv1gp120‏ ‎‡A  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.‏ ‎‡9  1‏
919 ‎‡a  presentingnativelikehiv1envelopetrimersonferritinnanoparticlesimprovestheirimmunogenicity‏ ‎‡A  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity‏ ‎‡9  1‏
919 ‎‡a  potentandbroadneutralizingantibodyrecognizesandpenetratesthehivglycanshield‏ ‎‡A  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield‏ ‎‡9  1‏
919 ‎‡a  structuraldelineationofaquaternarycleavagedependentepitopeatthegp41gp120interfaceonintacthiv1envtrimers‏ ‎‡A  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers‏ ‎‡9  1‏
919 ‎‡a  structureandimmunogenicityofastabilizedhiv1envelopetrimerbasedonagroup1000consensussequence‏ ‎‡A  Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence‏ ‎‡9  1‏
919 ‎‡a  supersiteofimmunevulnerabilityontheglycosylatedfaceofhiv1envelopeglycoproteingp120‏ ‎‡A  Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120‏ ‎‡9  1‏
919 ‎‡a  sustainedantigenavailabilityduringgerminalcenterinitiationenhancesantibodyresponsestovaccination‏ ‎‡A  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination‏ ‎‡9  1‏
919 ‎‡a  sustainedreleaseoftheccr5inhibitorscmpd167andmaravirocfromvaginalringsinrhesusmacaques‏ ‎‡A  Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques‏ ‎‡9  1‏
919 ‎‡a  potentinductionofantibodysecretingbcellsbyhumandermalderivedcd14+dendriticcellstriggeredbydualtolllikereceptorligation‏ ‎‡A  Potent induction of antibody-secreting B-cells by human dermal-derived CD14+ dendritic cells triggered by dual toll-like receptor ligation‏ ‎‡9  1‏
919 ‎‡a  tcellinducingvaccinedurablypreventsmucosalshivinfectionevenwithlowerneutralizingantibodytiters‏ ‎‡A  T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers‏ ‎‡9  1‏
919 ‎‡a  tailoreddesignofproteinnanoparticlescaffoldsformultivalentpresentationofviralglycoproteinantigens‏ ‎‡A  Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens‏ ‎‡9  1‏
919 ‎‡a  targetinghiv1envelopeglycoproteintrimerstobcellsbyusingaprilimprovesantibodyresponses‏ ‎‡A  Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses‏ ‎‡9  1‏
919 ‎‡a  potentinductionofantibodysecretingbcellsbyhumandermalderivedcd14+dendriticcellstriggeredbydualtlrligation‏ ‎‡A  Potent induction of antibody-secreting B cells by human dermal-derived CD14+ dendritic cells triggered by dual TLR ligation‏ ‎‡9  1‏
919 ‎‡a  testingonaprobebiosensorsrevealassociationofearlysarscov2totalantibodiesandsurrogateneutralizingantibodieswithmortalityincovid19patients‏ ‎‡A  Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients‏ ‎‡9  1‏
919 ‎‡a  harmsofpromotingthelableakhypothesisforsarscov2originswithoutevidence‏ ‎‡A  The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence‏ ‎‡9  1‏
919 ‎‡a  pharmacokineticsandefficacyofavaginallyadministeredmaravirocgelinrhesusmacaques‏ ‎‡A  Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques‏ ‎‡9  1‏
919 ‎‡a  impactofenvelopeglycoproteincleavageontheantigenicityinfectivityandneutralizationsensitivityofenvpseudotypedhumanimmunodeficiencyvirustype1particles‏ ‎‡A  The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles‏ ‎‡9  1‏
919 ‎‡a  partialprotectionagainstmultiplertshiv162p3vaginalchallengeofrhesusmacaquesbyasiliconeelastomervaginalringreleasingthennrti1000‏ ‎‡A  Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220.‏ ‎‡9  1‏
919 ‎‡a  partialenzymaticdeglycosylationpreservesthestructureofcleavedrecombinanthiv1envelopeglycoproteintrimers‏ ‎‡A  Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers‏ ‎‡9  1‏
919 ‎‡a  p0505enhancedimmunogenicityofhiv1envelopeglycoproteintrimersfusedtocd40ligand‏ ‎‡A  P05-05. Enhanced immunogenicity of HIV-1 envelope glycoprotein trimers fused to CD40 ligand.‏ ‎‡9  1‏
919 ‎‡a  optimizingtheproductionandaffinitypurificationofhiv1envelopeglycoproteinsosiptrimersfromtransientlytransfectedchocells‏ ‎‡A  Optimizing the production and affinity purification of HIV-1 envelope glycoprotein SOSIP trimers from transiently transfected CHO cells‏ ‎‡9  1‏
919 ‎‡a  pleaforjusticeforjailedmedicalworkers‏ ‎‡A  A Plea for Justice for Jailed Medical Workers‏ ‎‡9  1‏
919 ‎‡a  nextgenerationcleavedsolublehiv1envtrimerbg505sosip664gp140expressesmultipleepitopesforbroadlyneutralizingbutnotnonneutralizingantibodies‏ ‎‡A  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies‏ ‎‡9  1‏
919 ‎‡a  newglycandependentcd4bindingsiteneutralizingantibodyexertspressureonhiv1invivo‏ ‎‡A  A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo‏ ‎‡9  1‏
919 ‎‡a  oligomericandconformationalpropertiesofaproteolyticallymaturedisulfidestabilizedhumanimmunodeficiencyvirustype1gp140envelopeglycoprotein‏ ‎‡A  Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein‏ ‎‡9  1‏
919 ‎‡a  occludingthemannosemoietiesonhumanimmunodeficiencyvirustype1gp120withgriffithsinimprovestheantibodyresponsestobothproteinsinmice‏ ‎‡A  Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.‏ ‎‡9  1‏
919 ‎‡a  nonaqueoussiliconeelastomergelsasavaginalmicrobicidedeliverysystemforthehiv1entryinhibitormaraviroc‏ ‎‡A  Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.‏ ‎‡9  1‏
919 ‎‡a  neutralizingantibodyresponsesinducedbyhiv1envelopeglycoproteinsosiptrimersderivedfromeliteneutralizers‏ ‎‡A  Neutralizing antibody responses induced by HIV-1 envelope glycoprotein SOSIP trimers derived from elite neutralizers‏ ‎‡9  1‏
919 ‎‡a  neutralizingantibodyinductionbyhiv1envelopeglycoproteinsosiptrimersonironoxidenanoparticlesmaybeimpairedbymannosebindinglectin‏ ‎‡A  Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin‏ ‎‡9  1‏
919 ‎‡a  nativelikesosip664trimerbasedonanhiv1subtypebenvgene‏ ‎‡A  A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene‏ ‎‡9  1‏
919 ‎‡a  nativelikeenvtrimersasaplatformforhiv1vaccinedesign‏ ‎‡A  Native-like Env trimers as a platform for HIV-1 vaccine design‏ ‎‡9  1‏
919 ‎‡a  nterminalsubstitutionsinhiv1gp41reducetheexpressionofnontrimericenvelopeglycoproteinsonthevirus‏ ‎‡A  N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus‏ ‎‡9  1‏
919 ‎‡a  monoclonalantibodytocd4domain2blockssolublecd4inducedconformationalchangesintheenvelopeglycoproteinsofhumanimmunodeficiencyvirustype1hiv1andhiv1infectionofcd4+cells‏ ‎‡A  A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells‏ ‎‡9  1‏
919 ‎‡a  murineantibodyresponsestocleavedsolublehiv1envelopetrimersarehighlyrestrictedinspecificity‏ ‎‡A  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity‏ ‎‡9  1‏
919 ‎‡a  multipleccr5conformationsonthecellsurfaceareuseddifferentiallybyhumanimmunodeficiencyvirusesresistantorsensitivetoccr5inhibitors‏ ‎‡A  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.‏ ‎‡9  1‏
919 ‎‡a  comparativeimmunogenicitystudyinrabbitsofdisulfidestabilizedproteolyticallycleavedsolubletrimerichumanimmunodeficiencyvirustype1gp140trimericcleavagedefectivegp140andmonomericgp120‏ ‎‡A  A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.‏ ‎‡9  1‏
919 ‎‡a  mappingtheimmunogeniclandscapeofnearnativehiv1envelopetrimersinnonhumanprimates‏ ‎‡A  Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates‏ ‎‡9  1‏
919 ‎‡a  macaquestudiesofvaccineandmicrobicidecombinationsforpreventinghiv1sexualtransmission‏ ‎‡A  Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission‏ ‎‡9  1‏
919 ‎‡a  limitedornoprotectionbyweaklyornonneutralizingantibodiesagainstvaginalshivchallengeofmacaquescomparedwithastronglyneutralizingantibody‏ ‎‡A  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody‏ ‎‡9  1‏
919 ‎‡a  lackofcomplexnglycansonhiv1envelopeglycoproteinspreservesproteinconformationandentryfunction‏ ‎‡A  Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function‏ ‎‡9  1‏
919 ‎‡a  chimerichiv1envelopeglycoproteintrimerwithanembeddedgranulocytemacrophagecolonystimulatingfactorgmcsfdomaininducesenhancedantibodyandtcellresponses‏ ‎‡A  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses‏ ‎‡9  1‏
919 ‎‡a  isthereenoughgp120inthebodyfluidsofhiv1infectedindividualstohavebiologicallysignificanteffects‏ ‎‡A  Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?‏ ‎‡9  1‏
919 ‎‡a  integrityofglycosylationprocessingofaglycandepletedtrimerichiv1immunogentargetingkeybcelllineages‏ ‎‡A  Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages‏ ‎‡9  1‏
919 ‎‡a  influencesontrimerizationandaggregationofsolublecleavedhiv1sosipenvelopeglycoprotein‏ ‎‡A  Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein‏ ‎‡9  1‏
919 ‎‡a  stabilizedhiv1envelopeglycoproteintrimerfusedtocd40ligandtargetsandactivatesdendriticcells‏ ‎‡A  A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells‏ ‎‡9  1‏
919 ‎‡a  influencesonthedesignandpurificationofsolublerecombinantnativelikehiv1envelopeglycoproteintrimers‏ ‎‡A  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers‏ ‎‡9  1‏
919 ‎‡a  affinitymaturationofapotentfamilyofhivantibodiesisprimarilyfocusedonaccommodatingoravoidingglycans‏ ‎‡A  Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.‏ ‎‡9  1‏
919 ‎‡a  aidshivastepintodarknessorlight‏ ‎‡A  AIDS/HIV. A STEP into darkness or light?‏ ‎‡9  1‏
919 ‎‡a  inefficiententryofvicrivirocresistanthiv1viatheinhibitorccr5complexatlowcellsurfaceccr5densities‏ ‎‡A  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities‏ ‎‡9  1‏
919 ‎‡a  hiv1antibodyfromaneliteneutralizerimplicatesthefusionpeptideasasiteofvulnerability‏ ‎‡A  An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability‏ ‎‡9  1‏
919 ‎‡a  hiv1envelopeglycoproteintrimerwithanembeddedil21domainactivateshumanbcells‏ ‎‡A  An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells‏ ‎‡9  1‏
919 ‎‡a  improvingtheimmunogenicityofnativelikehiv1envelopetrimersbyhyperstabilization‏ ‎‡A  Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization‏ ‎‡9  1‏
919 ‎‡a  animalmodelsformicrobicidestudies‏ ‎‡A  Animal models for microbicide studies‏ ‎‡9  1‏
919 ‎‡a  improvingtheexpressionandpurificationofsolublerecombinantnativelikehiv1envelopeglycoproteintrimersbytargetedsequencechanges‏ ‎‡A  Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.‏ ‎‡9  1‏
919 ‎‡a  mannosedependentepitopeforneutralizingantibody2g12onhumanimmunodeficiencyvirustype1glycoproteingp120‏ ‎‡A  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.‏ ‎‡9  1‏
919 ‎‡a  immunogenicityofstabilizedhiv1envelopetrimerswithreducedexposureofnonneutralizingepitopes‏ ‎‡A  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes‏ ‎‡9  1‏
919 ‎‡a  immunogenicityinrabbitsofsosiptrimersfromcladesaband100givenindividuallysequentiallyorincombinations‏ ‎‡A  Immunogenicity in rabbits of SOSIP trimers from clades A, B and C, given individually, sequentially or in combinations‏ ‎‡9  1‏
919 ‎‡a  immunizationforhiv1broadlyneutralizingantibodiesinhumanigknockinmice‏ ‎‡A  Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice‏ ‎‡9  1‏
919 ‎‡a  iggsubclassprofilesininfectedhivtype1controllersandchronicprogressorsandinuninfectedrecipientsofenvvaccines‏ ‎‡A  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines‏ ‎‡9  1‏
919 ‎‡a  humanimmunodeficiencyvirustype1attachmentcoreceptorandfusioninhibitorsareactiveagainstbothdirectandtransinfectionofprimarycells‏ ‎‡A  Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells‏ ‎‡9  1‏
919 ‎‡a  thermodynamicandkineticanalysisofscd4bindingtohiv1virionsandofgp120dissociation‏ ‎‡A  Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation‏ ‎‡9  1‏
919 ‎‡a  howcanhivtype1envimmunogenicitybeimprovedtofacilitateantibodybasedvaccinedevelopment‏ ‎‡A  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?‏ ‎‡9  1‏
919 ‎‡a  hivsachillesheel‏ ‎‡A  HIV's Achilles' Heel‏ ‎‡9  1‏
919 ‎‡a  hivastampontheenvelope‏ ‎‡A  HIV: A stamp on the envelope‏ ‎‡9  1‏
919 ‎‡a  hiv1vaccineshiv1neutralizingantibodiesinducedbynativelikeenvelopetrimers‏ ‎‡A  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers‏ ‎‡9  1‏
919 ‎‡a  hiv1pathogenesisthecomplexitiesoftheccr5ccl3l1complex‏ ‎‡A  HIV-1 pathogenesis: the complexities of the CCR5-CCL3L1 complex‏ ‎‡9  1‏
919 ‎‡a  transmittedfounderandchronichiv1envelopeproteinsaredistinguishedbydifferentialutilizationofccr5‏ ‎‡A  Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.‏ ‎‡9  1‏
919 ‎‡a  hiv1neutralizingantibodyinducedbysimianadenovirusandpoxvirusmvavectoredbg505nativelikeenvelopetrimers‏ ‎‡A  HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers‏ ‎‡9  1‏
919 ‎‡a  hiv1gp120mannosesinduceimmunosuppressiveresponsesfromdendriticcells‏ ‎‡A  HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells‏ ‎‡9  1‏
919 ‎‡a  hiv1gp120impairstheinductionofbcellresponsesbytlr9activatedplasmacytoiddendriticcells‏ ‎‡A  HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells‏ ‎‡9  1‏
919 ‎‡a  hiv1envelopetrimerdesignandimmunizationstrategiestoinducebroadlyneutralizingantibodies‏ ‎‡A  HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies‏ ‎‡9  1‏
919 ‎‡a  hiv1envelopetriggerspolyclonaligclassswitchrecombinationthroughacd40independentmechanisminvolvingbaffand100typelectinreceptors‏ ‎‡A  HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors‏ ‎‡9  1‏
919 ‎‡a  trimerichiv1glycoproteingp140immunogensandnativehiv1envelopeglycoproteinsdisplaythesameclosedandopenquaternarymoleculararchitectures‏ ‎‡A  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures‏ ‎‡9  1‏
919 ‎‡a  highthroughputproteinengineeringimprovestheantigenicityandstabilityofsolublehiv1envelopeglycoproteinsosiptrimers‏ ‎‡A  High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers‏ ‎‡9  1‏
919 ‎‡a  goodcopbadcopinterrogatingtheimmuneresponsestoprimatelentiviralvaccines‏ ‎‡A  Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines‏ ‎‡9  1‏
919 ‎‡a  glycandependentimmunogenicityofrecombinantsolubletrimerichemagglutinin‏ ‎‡A  Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin‏ ‎‡9  1‏
919 ‎‡a  evolutionaryrepairofhivtype1gp41withakinkinthenterminalhelixleadstorestorationofthe6helixbundlestructure‏ ‎‡A  Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure‏ ‎‡9  1‏
919 ‎‡a  evolutionofthehiv1envelopeglycoproteinswithadisulfidebondbetweengp120andgp41‏ ‎‡A  Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41‏ ‎‡9  1‏
919 ‎‡a  evaluatingtheimmunogenicityofadisulfidestabilizedcleavedtrimericformoftheenvelopeglycoproteincomplexofhumanimmunodeficiencyvirustype1‏ ‎‡A  Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1‏ ‎‡9  1‏
919 ‎‡a  epitopesforneutralizingantibodiesinducedbyhiv1envelopeglycoproteinbg505sosiptrimersinrabbitsandmacaques‏ ‎‡A  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.‏ ‎‡9  1‏
919 ‎‡a  enzymaticremovalofmannosemoietiescanincreasetheimmuneresponsetohiv1gp120invivo‏ ‎‡A  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo‏ ‎‡9  1‏
919 ‎‡a  envglycoproteinheterogeneityasasourceofapparentsynergyandenhancedcooperativityininhibitionofhiv1infectionbyneutralizingantibodiesandentryinhibitors‏ ‎‡A  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors‏ ‎‡9  1‏
919 ‎‡a  tropismindependentprotectionofmacaquesagainstvaginaltransmissionof3shivsbythehiv1fusioninhibitort‏ ‎‡A  Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.‏ ‎‡9  1‏
919 ‎‡a  envexceptionalismwhyarehiv1envglycoproteinsatypicalimmunogens‏ ‎‡A  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?‏ ‎‡9  1‏
919 ‎‡a  entryinhibitorssch100rantesandt20blockhivtype1replicationinmultiplecelltypes‏ ‎‡A  Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types‏ ‎‡9  1‏
919 ‎‡a  entryinhibitorbasedmicrobicidesareactiveinvitroagainsthiv1isolatesfrommultiplegeneticsubtypes‏ ‎‡A  Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes‏ ‎‡9  1‏
919 ‎‡a  2hiv1variantsresistanttosmallmoleculeccr5inhibitorsdifferinhowtheyuseccr5forentry‏ ‎‡A  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry‏ ‎‡9  1‏
919 ‎‡a  enhancingtheproteolyticmaturationofhumanimmunodeficiencyvirustype1envelopeglycoproteins‏ ‎‡A  Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins‏ ‎‡9  1‏
919 ‎‡a  useofasmallmoleculeccr5inhibitorinmacaquestotreatsimianimmunodeficiencyvirusinfectionorpreventsimianhumanimmunodeficiencyvirusinfection‏ ‎‡A  Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.‏ ‎‡9  1‏
919 ‎‡a  useofgproteincoupledanduncoupledccr5receptorsbyccr5inhibitorresistantandsensitivehumanimmunodeficiencyvirustype1variants‏ ‎‡A  Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.‏ ‎‡9  1‏
919 ‎‡a  v3determinantsofhiv1escapefromtheccr5inhibitorsmaravirocandvicriviroc‏ ‎‡A  V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc‏ ‎‡9  1‏
919 ‎‡a  v3hivsswitchhitter‏ ‎‡A  V3: HIV's switch-hitter‏ ‎‡9  1‏
919 ‎‡a  whatdochaotropebasedavidityassaysforantibodiestohiv1envelopeglycoproteinsmeasure‏ ‎‡A  What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?‏ ‎‡9  1‏
919 ‎‡a  whichtopicalmicrobicidesforblockinghiv1transmissionwillworkintherealworld‏ ‎‡A  Which topical microbicides for blocking HIV-1 transmission will work in the real world?‏ ‎‡9  1‏
919 ‎‡a  enhancingandshapingtheimmunogenicityofnativelikehiv1envelopetrimerswitha2componentproteinnanoparticle‏ ‎‡A  Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle‏ ‎‡9  1‏
919 ‎‡a  effectsofsequencechangesinthehiv1gp41fusionpeptideonccr5inhibitorresistance‏ ‎‡A  Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance‏ ‎‡9  1‏
919 ‎‡a  effectsofadjuvantsonhiv1envelopeglycoproteinsosiptrimersinvitro‏ ‎‡A  Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro.‏ ‎‡9  1‏
919 ‎‡a  effectofaccr5inhibitoronviralloadsinmacaquesdualinfectedwithr5andx4primateimmunodeficiencyviruses‏ ‎‡A  Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses‏ ‎‡9  1‏
919 ‎‡a  dominantnegativeeffectofheterooligomerizationonthefunctionofthehumanimmunodeficiencyvirustype1envelopeglycoproteincomplex‏ ‎‡A  Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.‏ ‎‡9  1‏
919 ‎‡a  directprobingofgerminalcenterresponsesrevealsimmunologicalfeaturesandbottlenecksforneutralizingantibodyresponsestohivenvtrimer‏ ‎‡A  Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer‏ ‎‡9  1‏
919 ‎‡a  differentialregulationoftheantibodyresponsestogagandenvproteinsofhumanimmunodeficiencyvirustype1‏ ‎‡A  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1‏ ‎‡9  1‏
919 ‎‡a  pharmacokineticsofaccr5inhibitorinrhesusmacaquesfollowingvaginalrectalandoralapplication‏ ‎‡A  Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application‏ ‎‡9  1‏
919 ‎‡a  antibodiestoaconformationalepitopeongp41neutralizehiv1bydestabilizingtheenvspike‏ ‎‡A  Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike‏ ‎‡9  1‏
919 ‎‡a  antibodiestosarscov2andtheirpotentialfortherapeuticpassiveimmunization‏ ‎‡A  Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization‏ ‎‡9  1‏
919 ‎‡a  antibodypotencyrelatestotheabilitytorecognizetheclosedprefusionformofhivenv‏ ‎‡A  Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env‏ ‎‡9  1‏
919 ‎‡a  antibodyresponseselicitedbyimmunizationwithbg505trimerimmunecomplexes‏ ‎‡A  Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes‏ ‎‡9  1‏
919 ‎‡a  antiretroviraldrugbasedmicrobicidestopreventhiv1sexualtransmission‏ ‎‡A  Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission‏ ‎‡9  1‏
919 ‎‡a  asymmetricrecognitionofthehiv1trimerbybroadlyneutralizingantibodypg9‏ ‎‡A  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.‏ ‎‡9  1‏
919 ‎‡a  autoantibodiesinducedbychimericcytokinehivenvelopeglycoproteinimmunogens‏ ‎‡A  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.‏ ‎‡9  1‏
919 ‎‡a  bindingofinferredgermlineprecursorsofbroadlyneutralizinghiv1antibodiestonativelikeenvelopetrimers‏ ‎‡A  Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.‏ ‎‡9  1‏
919 ‎‡a  broadlyneutralizingantibodypgt121allostericallymodulatescd4bindingviarecognitionofthehiv1gp120v3baseandmultiplesurroundingglycans‏ ‎‡A  Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans‏ ‎‡9  1‏
919 ‎‡a  broadlyneutralizinghivantibodiesdefineaglycandependentepitopeontheprefusionconformationofgp41oncleavedenvelopetrimers‏ ‎‡A  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers‏ ‎‡9  1‏
919 ‎‡a  capturingtheinherentstructuraldynamicsofthehiv1envelopeglycoproteinfusionpeptide‏ ‎‡A  Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide‏ ‎‡9  1‏
919 ‎‡a  cd4inducedactivationinasolublehiv1envtrimer‏ ‎‡A  CD4-induced activation in a soluble HIV-1 Env trimer‏ ‎‡9  1‏
919 ‎‡a  cellsurfaceexpressionofccr5andotherhostfactorsinfluencetheinhibitionofhiv1infectionofhumanlymphocytesbyccr5ligands‏ ‎‡A  Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands‏ ‎‡9  1‏
919 ‎‡a  cgmpproductionandanalysisofbg505sosip664anextensivelyglycosylatedtrimerichiv1envelopeglycoproteinvaccinecandidate‏ ‎‡A  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate‏ ‎‡9  1‏
919 ‎‡a  cleavagestronglyinfluenceswhethersolublehiv1envelopeglycoproteintrimersadoptanativelikeconformation‏ ‎‡A  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation‏ ‎‡9  1‏
919 ‎‡a  clinicaladjuvantcombinationsstimulatepotentbcellresponsesinvitrobyactivatingdermaldendriticcells‏ ‎‡A  Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells‏ ‎‡9  1‏
919 ‎‡a  closingandopeningholesintheglycanshieldofhiv1envelopeglycoproteinsosiptrimerscanredirecttheneutralizingantibodyresponsetothenewlyunmaskedepitopes‏ ‎‡A  Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes‏ ‎‡9  1‏
919 ‎‡a  comparativeimmunogenicityofevolvedv1v2deletedhiv1envelopeglycoproteintrimers‏ ‎‡A  Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers‏ ‎‡9  1‏
919 ‎‡a  comprehensiveantigenicmapofacleavedsolublehiv1envelopetrimer‏ ‎‡A  Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer‏ ‎‡9  1‏
919 ‎‡a  conformationalplasticityinthehiv1fusionpeptidefacilitatesrecognitionbybroadlyneutralizingantibodies‏ ‎‡A  Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies‏ ‎‡9  1‏
919 ‎‡a  cryoemstructureofafullyglycosylatedsolublecleavedhiv1envelopetrimer‏ ‎‡A  Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer‏ ‎‡9  1‏
919 ‎‡a  crystalstructureofasolublecleavedhiv1envelopetrimer‏ ‎‡A  Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer‏ ‎‡9  1‏
919 ‎‡a  designandcrystalstructureofanativelikehiv1envelopetrimerthatengagesmultiplebroadlyneutralizingantibodyprecursorsinvivo‏ ‎‡A  Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.‏ ‎‡9  1‏
919 ‎‡a  designandstructureof2hiv1clade100sosip664trimersthatincreasethearsenalofnativelikeenvimmunogens‏ ‎‡A  Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens‏ ‎‡9  1‏
919 ‎‡a  developabilityassessmentofphysicochemicalpropertiesandstabilityprofilesofhiv1bg505sosip664andbg505sosipv41gt11gp140envelopeglycoproteintrimersascandidatevaccineantigens‏ ‎‡A  Developability Assessment of Physicochemical Properties and Stability Profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 Envelope Glycoprotein Trimers as Candidate Vaccine Antigens‏ ‎‡9  1‏
919 ‎‡a  developmentalpathwayforpotentv1v2directedhivneutralizingantibodies‏ ‎‡A  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies‏ ‎‡9  1‏
919 ‎‡a  differentialbindingofneutralizingandnonneutralizingantibodiestonativelikesolublehiv1envtrimersuncleavedenvproteinsandmonomericsubunits‏ ‎‡A  Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits‏ ‎‡9  1‏
919 ‎‡a  resistancetoccr5inhibitorscausedbysequencechangesinthefusionpeptideofhiv1gp41‏ ‎‡A  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.‏ ‎‡9  1‏
943 ‎‡a  122x‏ ‎‡A  1220‏ ‎‡9  1‏
943 ‎‡a  124x‏ ‎‡A  1249‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  LIH|LNB:OJ_s_;=B_i_‏
996 ‎‡2  ISNI|0000000399350344‏
996 ‎‡2  NDL|01098299‏
996 ‎‡2  NUKAT|n 96403628‏
996 ‎‡2  CAOONL|ncf10391074‏
996 ‎‡2  CAOONL|ncf10534820‏
996 ‎‡2  LC|n 97022648‏
996 ‎‡2  NLA|000035912724‏
996 ‎‡2  LC|n 96040677‏
996 ‎‡2  BNF|16160639‏
996 ‎‡2  ISNI|0000000039573034‏
996 ‎‡2  ISNI|0000000117963813‏
996 ‎‡2  LIH|LNB:C_n__w_E;=B9‏
996 ‎‡2  LC|n 92103384‏
996 ‎‡2  ISNI|000000007988577X‏
996 ‎‡2  BIBSYS|8064661‏
996 ‎‡2  LC|n 93040909‏
996 ‎‡2  BNF|12043772‏
996 ‎‡2  LC|nb2006010492‏
996 ‎‡2  CAOONL|ncf10281140‏
996 ‎‡2  NUKAT|n 2009141651‏
996 ‎‡2  DNB|120115352‏
996 ‎‡2  ISNI|0000000039376612‏
996 ‎‡2  NUKAT|n 00092054‏
996 ‎‡2  CAOONL|ncf11352865‏
996 ‎‡2  DNB|1013550226‏
996 ‎‡2  ISNI|0000000103054045‏
996 ‎‡2  NDL|00740239‏
996 ‎‡2  BIBSYS|90086472‏
996 ‎‡2  PLWABN|9810554016905606‏
996 ‎‡2  LC|no2010085097‏
996 ‎‡2  BIBSYS|90249283‏
996 ‎‡2  NTA|071513175‏
996 ‎‡2  ISNI|000000004437964X‏
996 ‎‡2  LC|no 92029842‏
996 ‎‡2  ISNI|000000004774119X‏
996 ‎‡2  DNB|1159328730‏
996 ‎‡2  CAOONL|ncf11212385‏
996 ‎‡2  NKC|pna20191025778‏
996 ‎‡2  BIBSYS|97051451‏
996 ‎‡2  ISNI|0000000047698670‏
996 ‎‡2  NII|DA02206528‏
996 ‎‡2  LC|nb2018007867‏
996 ‎‡2  ISNI|0000000077652489‏
996 ‎‡2  LC|n 2006017323‏
996 ‎‡2  SUDOC|185281397‏
996 ‎‡2  ISNI|0000000110727500‏
996 ‎‡2  LC|no2023019632‏
996 ‎‡2  SUDOC|180902563‏
996 ‎‡2  NLA|000035360909‏
996 ‎‡2  ISNI|0000000446200171‏
996 ‎‡2  LC|n 2007064266‏
996 ‎‡2  DNB|120974525‏
996 ‎‡2  NTA|229559077‏
996 ‎‡2  CAOONL|ncf10157628‏
996 ‎‡2  LC|n 50004284‏
996 ‎‡2  NUKAT|n 2017220927‏
996 ‎‡2  LC|n 50004280‏
996 ‎‡2  SUDOC|187540594‏
996 ‎‡2  SUDOC|060306378‏
996 ‎‡2  LC|nr 98038597‏
996 ‎‡2  NKC|jcu2012739673‏
996 ‎‡2  ISNI|0000000030968494‏
996 ‎‡2  LC|no2005079202‏
996 ‎‡2  RERO|A012543682‏
996 ‎‡2  LC|nb2002069793‏
996 ‎‡2  ISNI|0000000453046539‏
996 ‎‡2  ISNI|0000000117336940‏
996 ‎‡2  B2Q|0000070043‏
996 ‎‡2  SUDOC|181040697‏
996 ‎‡2  NKC|xx0218578‏
996 ‎‡2  BIBSYS|41837‏
996 ‎‡2  ISNI|000000003334891X‏
996 ‎‡2  ISNI|0000000474707594‏
996 ‎‡2  LC|n 95111328‏
996 ‎‡2  LC|n 96091723‏
996 ‎‡2  RERO|A003606950‏
996 ‎‡2  RERO|A003606951‏
996 ‎‡2  LC|n 82240746‏
996 ‎‡2  CAOONL|ncf11273573‏
996 ‎‡2  NII|DA0091617X‏
996 ‎‡2  LIH|LNB:V-334198;=BO‏
996 ‎‡2  J9U|987012449349105171‏
996 ‎‡2  ISNI|0000000054804750‏
996 ‎‡2  NTA|374847967‏
996 ‎‡2  PTBNP|507007‏
996 ‎‡2  LC|nr 99005140‏
996 ‎‡2  NTA|074957899‏
996 ‎‡2  LC|n 89640704‏
996 ‎‡2  BIBSYS|2017825‏
996 ‎‡2  LC|no 95015600‏
996 ‎‡2  NUKAT|n 2010142315‏
996 ‎‡2  NUKAT|nx2023543353‏
996 ‎‡2  CAOONL|ncf10036710‏
996 ‎‡2  CAOONL|ncf10093929‏
996 ‎‡2  J9U|987007460103005171‏
996 ‎‡2  DNB|173091385‏
996 ‎‡2  NLA|000035974533‏
996 ‎‡2  ISNI|0000000024478659‏
996 ‎‡2  LC|nr 94002311‏
996 ‎‡2  LC|n 83188922‏
996 ‎‡2  J9U|987007454731905171‏
996 ‎‡2  LC|no2019131663‏
996 ‎‡2  RERO|A012328865‏
996 ‎‡2  LC|no2017008363‏
996 ‎‡2  DNB|1158362692‏
996 ‎‡2  DNB|172956420‏
996 ‎‡2  N6I|vtls000287066‏
996 ‎‡2  RERO|A011657989‏
996 ‎‡2  SUDOC|130161969‏
996 ‎‡2  BNF|14473355‏
996 ‎‡2  LC|n 86005411‏
996 ‎‡2  N6I|vtls002600978‏
996 ‎‡2  CAOONL|ncf10100884‏
996 ‎‡2  SUDOC|07748746X‏
996 ‎‡2  BIBSYS|90810173‏
996 ‎‡2  NII|DA06493909‏
996 ‎‡2  CAOONL|ncf12119949‏
996 ‎‡2  DNB|139840621‏
996 ‎‡2  ISNI|0000000009255158‏
996 ‎‡2  ISNI|0000000111185109‏
996 ‎‡2  SUDOC|148514154‏
996 ‎‡2  LC|n 2006030072‏
996 ‎‡2  PLWABN|9814147006105606‏
996 ‎‡2  NII|DA00790843‏
996 ‎‡2  LC|nb 90003766‏
996 ‎‡2  LC|nb2023000400‏
996 ‎‡2  ISNI|0000000078256867‏
996 ‎‡2  ISNI|000000045285696X‏
996 ‎‡2  LC|no 93033254‏
996 ‎‡2  DNB|109623064X‏
996 ‎‡2  SIMACOB|131246947‏
996 ‎‡2  ISNI|0000000117929308‏
996 ‎‡2  J9U|987007448863705171‏
996 ‎‡2  RERO|A022249188‏
996 ‎‡2  DNB|172956412‏
996 ‎‡2  LC|no2012003351‏
996 ‎‡2  LC|no 98019774‏
996 ‎‡2  CAOONL|ncf10527093‏
996 ‎‡2  LC|n 2015010031‏
996 ‎‡2  LC|no2022035574‏
996 ‎‡2  LC|n 2012057079‏
996 ‎‡2  LC|n 2019048509‏
996 ‎‡2  LC|no2003068134‏
996 ‎‡2  CAOONL|ncf11224182‏
996 ‎‡2  NTA|071673369‏
996 ‎‡2  ISNI|0000000048910370‏
996 ‎‡2  BIBSYS|90841902‏
996 ‎‡2  ISNI|0000000395191892‏
996 ‎‡2  BIBSYS|1671433161001‏
996 ‎‡2  BAV|495_113043‏
996 ‎‡2  J9U|987007434573405171‏
996 ‎‡2  B2Q|0000390253‏
996 ‎‡2  LC|n 80115775‏
996 ‎‡2  NTA|339730110‏
996 ‎‡2  ISNI|0000000050551637‏
996 ‎‡2  CAOONL|ncf11047450‏
996 ‎‡2  NUKAT|n 2006139198‏
996 ‎‡2  LNB|LNC10-000136882‏
996 ‎‡2  SUDOC|134177215‏
996 ‎‡2  LC|n 2021051537‏
996 ‎‡2  NTA|12118224X‏
996 ‎‡2  DNB|136264166‏
996 ‎‡2  LC|no2024009633‏
996 ‎‡2  ISNI|0000000114699703‏
996 ‎‡2  LC|no2015078901‏
996 ‎‡2  LC|nb2010022487‏
996 ‎‡2  DNB|1157886744‏
996 ‎‡2  J9U|987007463555505171‏
996 ‎‡2  J9U|987007345801705171‏
996 ‎‡2  NDL|00906219‏
996 ‎‡2  BIBSYS|10071983‏
996 ‎‡2  ISNI|0000000084379249‏
996 ‎‡2  NUKAT|n 2020210360‏
996 ‎‡2  DNB|1157924972‏
996 ‎‡2  N6I|vtls000888986‏
996 ‎‡2  LC|nr 97001533‏
996 ‎‡2  ISNI|0000000430377212‏
996 ‎‡2  LC|nr 97001534‏
996 ‎‡2  LC|no2013109050‏
996 ‎‡2  SUDOC|268752974‏
996 ‎‡2  NII|DA10316088‏
996 ‎‡2  NDL|00831849‏
996 ‎‡2  SUDOC|050469517‏
996 ‎‡2  LC|n 84038722‏
996 ‎‡2  NII|DA01704224‏
996 ‎‡2  ISNI|0000000108976639‏
996 ‎‡2  ISNI|0000000083910253‏
996 ‎‡2  BIBSYS|90281198‏
996 ‎‡2  SUDOC|227518152‏
996 ‎‡2  BNF|17128631‏
996 ‎‡2  LC|no2010156916‏
996 ‎‡2  ISNI|0000000084281575‏
996 ‎‡2  N6I|vtls000012468‏
996 ‎‡2  N6I|vtls000095977‏
996 ‎‡2  CAOONL|ncf11485248‏
996 ‎‡2  PLWABN|9810694545605606‏
996 ‎‡2  LC|no 97055390‏
996 ‎‡2  J9U|987007378318705171‏
996 ‎‡2  NKC|xx0214182‏
996 ‎‡2  ISNI|000000003927507X‏
996 ‎‡2  NUKAT|n 99003191‏
996 ‎‡2  LNB|LNC10-000081508‏
996 ‎‡2  LC|no2020066856‏
996 ‎‡2  BLBNB|000838531‏
996 ‎‡2  DNB|1073264548‏
996 ‎‡2  ISNI|0000000070916648‏
996 ‎‡2  LC|n 90633515‏
996 ‎‡2  N6I|vtls000285657‏
996 ‎‡2  ISNI|0000000084701912‏
996 ‎‡2  ISNI|0000000054795479‏
996 ‎‡2  ISNI|0000000387604685‏
996 ‎‡2  BIBSYS|5095244‏
996 ‎‡2  NDL|00471845‏
996 ‎‡2  DNB|1264172885‏
996 ‎‡2  NKC|mub20181011630‏
996 ‎‡2  NTA|395066972‏
996 ‎‡2  BLBNB|000581250‏
996 ‎‡2  NTA|427654696‏
996 ‎‡2  LC|n 87878486‏
996 ‎‡2  DNB|1185185569‏
996 ‎‡2  ISNI|000000003724929X‏
996 ‎‡2  NII|DA07011366‏
996 ‎‡2  NTA|069653739‏
996 ‎‡2  NDL|001284671‏
996 ‎‡2  BNF|12300418‏
996 ‎‡2  PLWABN|9813280256205606‏
996 ‎‡2  J9U|987007463554705171‏
996 ‎‡2  ISNI|0000000036338397‏
996 ‎‡2  ISNI|0000000049278864‏
996 ‎‡2  BNC|981058516170406706‏
996 ‎‡2  PLWABN|9810667198305606‏
996 ‎‡2  SUDOC|24917801X‏
996 ‎‡2  DNB|1112948260‏
996 ‎‡2  DNB|119518511‏
996 ‎‡2  BNF|15908768‏
996 ‎‡2  LC|n 87829764‏
996 ‎‡2  BNC|981058614908706706‏
996 ‎‡2  CAOONL|ncf12114030‏
996 ‎‡2  ISNI|0000000109029043‏
996 ‎‡2  SUDOC|178050571‏
996 ‎‡2  BNCHL|10000000000000000016550‏
996 ‎‡2  CAOONL|ncf10455735‏
996 ‎‡2  BNF|17838504‏
996 ‎‡2  B2Q|0000929368‏
996 ‎‡2  RERO|A025726992‏
996 ‎‡2  LC|n 85144057‏
996 ‎‡2  LC|no 96029904‏
996 ‎‡2  ISNI|0000000051487155‏
996 ‎‡2  DNB|1031582711‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏